CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Protocol to generate traceable CAR T cells for syngeneic mouse cancer models.
Protocol to generate traceable CAR T cells for syngeneic mouse cancer models.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞免疫疗法的疗效受到免疫抑制性肿瘤微环境导致的T细胞浸润和活化不足的限制。在免疫健全的小鼠癌症模型中使用优化的小鼠CAR-T 细胞进行临床前研究,将有助于阐明免疫治疗耐药的潜在机制。在此,我们介绍一种制备小鼠T细胞并生成CAR-T 细胞的方案。随后,我们详细描述在同基因小鼠胶质瘤模型中测试其治疗效果并追踪这些细胞的步骤。关于本方案使用和执行的完整细节,请参阅Zhang等。1。
The efficacy of chimeric antigen receptor (CAR) T cell immunotherapy is limited by insufficient infiltration and activation of T cells due to the immunosuppressive tumor microenvironment. Preclinical studies with optimized mouse CAR T cells in immunocompetent mouse cancer models will help define the mechanisms underlying immunotherapy resistance.
Here, we present a protocol for preparing mouse T cells and generating CAR T cells.
We then detail procedures for testing their therapeutic efficacy and tracking them in a syngeneic mouse glioma model. For complete details on the use and execution of this protocol, please refer to Zhang et al. 1 .
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。